Operating NPAT rose 1% to $59.7m and operating EBITDA grew 7%, while reported NPAT fell 52% due to fair value and tax adjustments. Global case sales declined 2%, but outperformed the NZ export market. The outlook targets 3.9m case sales by 2027 and continued investment in growth and sustainability.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.